Cervical cancer risk in women living with HIV across four continents: A multicohort study.

Rohner, E; Bütikofer, L; Schmidlin, K; Sengayi, M; Maskew, M; Giddy, J; Taghavi, K; Moore, RD; Goedert, JJ; Gill, MJ; Silverberg, MJ; DSouza, G; Patel, P; Castilho, JL; Ross, J; Sohn, A; Bani-Sadr, F; Taylor, N; Paparizos, V; Bonnet, F; Verbon, A; Vehreschild, JJ; Post, FA; Sabin, C; Mocroft, A; Dronda, F; Obel, N; Grabar, S; Spagnuolo, V; Quiros-Roldan, E; Mussini, C; Miro, JM; Meyer, L; Hasse, B; Konopnicki, D; Roca, B; Barger, D; Clifford, GM; Franceschi, S; Egger, M; Bohlius, J; Int J Cancer. 2020; 146(3):601-609

Gemtuzumab Ozogamicin in

Schlenk, RF; Paschka, P; Krzykalla, J; Weber, D; Kapp-Schwoerer, S; Gaidzik, VI; Leis, C; Fiedler, W; Kindler, T; Schroeder, T; Mayer, K; Lübbert, M; Wattad, M; Götze, K; Horst, HA; Koller, E; Wulf, G; Schleicher, J; Bentz, M; Greil, R; Hertenstein, B; Krauter, J; Martens, U; Nachbaur, D; Abu Samra, M; Girschikofsky, M; Basara, N; Benner, A; Thol, F; Heuser, M; Ganser, A; Döhner, K; Döhner, H; J Clin Oncol. 2020; 38(6):623-632

„I was seen by a radiologist, but unfortunately I can“t remember the name and I still have questions. What should I do?“ Radiologists should give thoughts to improve service professionalism and patient esteem.

Gutzeit, A; Fischmann, A; Forstner, R; Goette, R; Herzog, B; Kurtz, C; Hebler, C; Ladinger, A; Froehlich, JM; Blautzik, J; Kolokythas, O; Matoori, S; Kos, S; Reischauer, C; Schefer, H; Dubsky, P; Gampenrieder, SP; Hergan, K; Gaissmaier, W; Koh, DM; Meissnitzer, M CANCER IMAGING. 2020; 20(1): 18

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).

Moehler, M; Maderer, A; Thuss-Patience, PC; Brenner, B; Meiler, J; Ettrich, TJ; Hofheinz, RD; Al-Batran, SE; Vogel, A; Mueller, L; Lutz, MP; Lordick, F; Alsina, M; Borchert, K; Greil, R; Eisterer, W; Schad, A; Slotta-Huspenina, J; Van Cutsem, E; Lorenzen, S ANN ONCOL. 2020; 31(2): 228-235.

Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network

Greinix, HT; Attarbaschi, A; Girschikofsky, M; Greil, R; Holter, W; Neumeister, P; Peters, C; Petzer, A; Rudzki, J; Schlenke, P; Schmitt, CA; Schwinger, W; Wolf, D; Worel, N; Jaeger, U MEMO-MAG EUR MED ONC. 2020;

TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia.

Szenes, E; Harzschel, A; Decker, S; Tissino, E; Pischeli, J; Gutjahr, JC; Kissel, S; Pennisi, S; Hopner, JP; Egle, A; Zaborsky, N; Dierks, C; Follo, M; Chigaev, A; Zucchetto, A; Greil, R; Gattei, V; Hartmann, TN LEUKEMIA. 2020; 34(9): 2498-2502.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Murthy, RK; Loi, S; Okines, A; Paplomata, E; Hamilton, E; Hurvitz, SA; Lin, NU; Borges, V; Abramson, V; Anders, C; Bedard, PL; Oliveira, M; Jakobsen, E; Bachelot, T; Shachar, SS; Müller, V; Braga, S; Duhoux, FP; Greil, R; Cameron, D; Carey, LA; Curigliano, G; Gelmon, K; Hortobagyi, G; Krop, I; Loibl, S; Pegram, M; Slamon, D; Palanca-Wessels, MC; Walker, L; Feng, W; Winer, EP; N Engl J Med. 2020; 382(7):597-609

Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis.

Haslbauer, F; Petzer, A; Safanda, M; Tomova, A; Porubska, M; Bajory, Z; Niepel, D; Jaeger, C; Bjorklof, K; Kalinin, D; Greil, R; Support Care Cancer. 2020; 28(4):1855-1865

Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance.

Park, E; Chen, J; Moore, A; Mangolini, M; Santoro, A; Boyd, JR; Schjerven, H; Ecker, V; Buchner, M; Williamson, JC; Lehner, PJ; Gasparoli, L; Williams, O; Bloehdorn, J; Stilgenbauer, S; Leitges, M; Egle, A; Schmidt-Supprian, M; Frietze, S; Ringshausen, I; Sci Transl Med. 2020; 12(526):

Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.

Hufnagl, C; Leisch, M; Weiss, L; Melchardt, T; Moik, M; Asslaber, D; Roland, G; Steininger, P; Meissnitzer, T; Neureiter, D; Greil, R; Egle, A; Oncol Lett. 2020; 19(2):-1558.